pharmaceutical daily

FDA pauses vaccination with J&J vaccine after six cases of blood clot

U.S. CDC and FDA called for a pause in the J&J’s vaccine use following the emergence of a rare blood clotting disorder in six recipients.
 
Agencies reported that all six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.
 
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S.
 
J&J said that they are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine.
Also, the company is reviewing cases with European health authorities and they will delay the rollout of the vaccine in Europe and pause vaccinations in all Janssen COVID-19 vaccine clinical trials while they update guidance for investigators and participants.
 
 
Exit mobile version